Lotte Biologics signed its first contract of the 12 months on the JP Morgan Healthcare Convention (JPMHC) 2026.
Lotte Biologics introduced on Jan. 13 (native time) that it had entered right into a contract manufacturing group (CMO) settlement for biopharmaceuticals with Japan’s Rakuten Medical. The contracted product is Rakuten Medical’s flagship drug, a head and neck most cancers therapy primarily based on photoimmunotherapy.
Photoimmunotherapy is a therapy technique that enhances each efficacy and security by combining a light-reactive substance with a goal antibody after which irradiating crimson mild to the tumor website to selectively destroy goal cells. This therapy has been commercialized in Japan after receiving conditional early approval. It’s at the moment present process world Section 3 medical trials in the USA and Taiwan, and medical trials are scheduled to begin in Ukraine and Poland.
Lotte Biologics will produce this at its Bio Campus in Syracuse, New York. An organization official mentioned, “We plan to actively help world medical and commercialization companies primarily based on our high-quality manufacturing system, steady provide functionality, and world regulatory response capability required for world medical trials and commercialization.”
Lotte Biologics’ Syracuse Bio Campus has lately begun full-scale operation of its antibody-drug conjugate (ADC) manufacturing services, strengthening its conjugation service capabilities. The primary plant on the Songdo Bio Campus in Incheon, Korea, is scheduled for completion in August of this 12 months. Based mostly on this, Lotte Biologics’ plan is to strengthen its place as a worldwide ADC contract growth and manufacturing group (CDMO) firm this 12 months.
Lotte Biologics will set up a provide chain with Rakuten Medical in levels, extending from the medical stage to commercialization. An organization official mentioned, “The mid- to long-term partnership for monoclonal antibody and ADC manufacturing cooperation has led to an precise contract,” including, “Utilizing this as a stepping stone, we are going to improve model recognition in world markets resembling the USA and Japan and proceed aggressive contracting actions.”
